183 related articles for article (PubMed ID: 36380710)
1. First-line levetiracetam versus enzyme-inducing antiseizure medication in glioma patients with epilepsy.
van der Meer PB; Maschio M; Dirven L; Taphoorn MJB; Koekkoek JAF;
Epilepsia; 2023 Jan; 64(1):162-169. PubMed ID: 36380710
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Antiseizure Medication Duotherapies in Patients With Glioma: A Multicenter Observational Cohort Study.
van der Meer PB; Dirven L; Fiocco M; Vos MJ; Kouwenhoven MCM; van den Bent MJ; Taphoorn MJB; Koekkoek JAF
Neurology; 2022 Sep; 99(10):e999-e1008. PubMed ID: 36219797
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Antiseizure Medication Triple Therapy in Patients With Glioma With Refractory Epilepsy: An Observational Cohort Study.
van der Meer PB; Dirven L; Fiocco M; Vos MJ; Kouwenhoven MCM; van den Bent MJ; Taphoorn MJB; Koekkoek JAF
Neurology; 2023 Apr; 100(14):e1488-e1496. PubMed ID: 36754633
[TBL] [Abstract][Full Text] [Related]
4. Levetiracetam as a first-line antiseizure medication in WHO grade 2 glioma: Time to seizure freedom and rates of treatment failure.
Fairclough S; Goodden J; Chumas P; Mathew R; Maguire M
Epilepsia; 2023 Apr; 64(4):857-865. PubMed ID: 36636895
[TBL] [Abstract][Full Text] [Related]
5. Initial levetiracetam versus valproate monotherapy in antiseizure medicine (ASM)-naïve pediatric patients with idiopathic generalized epilepsy with tonic-clonic seizures.
Abdelmesih SK; Elkhateeb N; Zakaria M; Girgis MY
Seizure; 2021 Oct; 91():263-270. PubMed ID: 34246881
[TBL] [Abstract][Full Text] [Related]
6. Impact of seizures and antiseizure medication on survival in patients with glioma.
Kumar TS; Afnan WM; Chan CY; Audrey C; Fong SL; Rajandram R; Lim KS; Narayanan V
J Neurooncol; 2022 Sep; 159(3):657-664. PubMed ID: 36036318
[TBL] [Abstract][Full Text] [Related]
7. First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid.
van der Meer PB; Dirven L; Fiocco M; Vos MJ; Kouwenhoven MCM; van den Bent MJ; Taphoorn MJB; Koekkoek JAF
Epilepsia; 2021 May; 62(5):1119-1129. PubMed ID: 33735464
[TBL] [Abstract][Full Text] [Related]
8. Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020.
Kılıç B; Serdaroğlu E; Polat BG; İnce T; Esenülkü G; Topçu Y; Serdaroğlu A; Haspolat Ş; Tekgül H; Okuyaz Ç; Cansu A; Aydın K
Seizure; 2022 Jul; 99():48-53. PubMed ID: 35594744
[TBL] [Abstract][Full Text] [Related]
9. Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy.
Hattori EY; Arakawa Y; Mineharu Y; Furukawa K; Terada Y; Yamao Y; Tanji M; Kikuchi T; Miyamoto S
BMC Cancer; 2023 Sep; 23(1):849. PubMed ID: 37697277
[TBL] [Abstract][Full Text] [Related]
10. Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
Chonan M; Saito R; Kanamori M; Osawa SI; Watanabe M; Suzuki H; Nakasato N; Tominaga T
Neurol Med Chir (Tokyo); 2020 Jan; 60(1):37-44. PubMed ID: 31748440
[TBL] [Abstract][Full Text] [Related]
11. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
[TBL] [Abstract][Full Text] [Related]
12. Levetiracetam versus Phenobarbital for Neonatal Seizures: A Retrospective Cohort Study.
Bättig L; Dünner C; Cserpan D; Rüegger A; Hagmann C; Schmitt B; Pisani F; Ramantani G
Pediatr Neurol; 2023 Jan; 138():62-70. PubMed ID: 36401982
[TBL] [Abstract][Full Text] [Related]
13. Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy.
Cerulli Irelli E; Cocchi E; Morano A; Gesche J; Caraballo RH; Lattanzi S; Strigaro G; Catania C; Ferlazzo E; Pascarella A; Casciato S; Quarato P; Pizzanelli C; Pulitano P; Giuliano L; Viola V; Mostacci B; Fortunato F; Marini C; Di Gennaro G; Gambardella A; Labate A; Operto FF; Giallonardo AT; Baykan B; Beier CP; Di Bonaventura C;
JAMA Neurol; 2023 Nov; 80(11):1174-1181. PubMed ID: 37782485
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide.
van Opijnen MP; van der Meer PB; Dirven L; Fiocco M; Kouwenhoven MCM; van den Bent MJ; Taphoorn MJB; Koekkoek JAF
J Neurooncol; 2021 Aug; 154(1):73-81. PubMed ID: 34196916
[TBL] [Abstract][Full Text] [Related]
15. Guidelines for Seizure Prophylaxis in Adults Hospitalized with Moderate-Severe Traumatic Brain Injury: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care Society.
Frontera JA; Gilmore EJ; Johnson EL; Olson D; Rayi A; Tesoro E; Ullman J; Yuan Y; Zafar SF; Rowe S
Neurocrit Care; 2024 Jun; 40(3):819-844. PubMed ID: 38316735
[TBL] [Abstract][Full Text] [Related]
16. Impact of timing of antiseizure medication withdrawal on seizure recurrence in glioma patients: a retrospective observational study.
van der Meer PB; Dirven L; Fiocco M; Vos MJ; Kerkhof M; Kouwenhoven MCM; van den Bent MJ; Taphoorn MJB; Koekkoek JAF
J Neurooncol; 2023 Sep; 164(3):545-555. PubMed ID: 37755633
[TBL] [Abstract][Full Text] [Related]
17. Trends in enzyme-inducing antiseizure medication use: A retrospective analysis among adults with epilepsy.
Gandelman-Marton R; Theitler J
Epilepsy Behav; 2024 Mar; 152():109662. PubMed ID: 38277853
[TBL] [Abstract][Full Text] [Related]
18. Complications associated with the use of enzyme-inducing and non-enzyme-inducing anti-seizure medications in the Japanese population: A retrospective cohort study.
Gao J; Seki T; Usami K; Fan D; Ikeda A; Kawakami K
Epilepsy Behav; 2022 Apr; 129():108610. PubMed ID: 35231856
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST).
Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Chiesa V; Dainese F; De Maria G; Didato G; Falcicchio G; Fanella M; Ferlazzo E; Fisco G; Gangitano M; Giallonardo AT; Giorgi FS; La Neve A; Mecarelli O; Montalenti E; Piazza F; Pulitano P; Quarato PP; Ranzato F; Rosati E; Tassi L; Di Bonaventura C;
CNS Drugs; 2021 Dec; 35(12):1289-1301. PubMed ID: 34476770
[TBL] [Abstract][Full Text] [Related]
20. Effect of levetiracetam and oxcarbazepine on 4-year fragility fracture risk among prepubertal and pubertal children with epilepsy.
Whitney DG; Caird MS; Hurvitz EA; Rajapakse CS; Fedak Romanowski EM
Epilepsia; 2021 Sep; 62(9):2180-2189. PubMed ID: 34250606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
